Praxis Precision Medicines PRAX 深 沪
等待开盘 08-18 09:30:00 美东时间
388.45
+21.640
+5.90%
华盛通- 最 高391.41
- 今 开371.97
- 成交量 17.59万股
- 最 低 370.08
- 昨 收 366.81
- 总市值 108.46亿
- 52周最高 391.41
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 37.19
- 委 比 20.00%
- 总股本 2792.00万
- 历史最高 914.265
- 量 比 1.09
- 振 幅 5.81%
- 历史最低 11.85
- 每 手 1
- 风险率 105.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股盘后 | 康耐视小升1.99%，Brookfield基础设施小升1.95%
康耐视小升1.99%；Brookfield基础设施小升1.95%；Gen Digital小升1.93%
08-08 06:10
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions Inc (NYSE:MSI) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 guidance above estimates. Motorola Solutions reported q...
08-06 22:01
财报速睇 | Praxis Precision Medicines 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.84亿美元，同比亏损扩大18.3%
华盛资讯8月6日讯，Praxis Precision Medicines公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.84亿美元，同比亏损扩大18.3%。
08-06 20:57
财报速睇 | Praxis Precision Medicines 2026财年Q2营收0.00亿美元，与去年同期持平；归母净利润亏损0.84亿美元，同比亏损扩大17.7%
华盛资讯8月6日讯，Praxis Precision Medicines公布2026财年Q2业绩，公司Q2营收0.00亿美元，与去年同期持平，归母净利润亏损0.84亿美元，同比亏损扩大17.7%。
08-06 20:47
Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over losses of $(3.31) per share from the same period last year.
08-06 20:03
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Praxis Precision Medicines reported progress on its CNS pipeline, including successful mid-cycle meetings for ulixacaltamide HCl and relutrigine with no major safety concerns from the FDA, and PDUFA dates set for January 2027 and December 2026, respectively. The company also completed FDA BIMO inspections without Form 483 observations. Commercial preparations are advancing for both programs. Additionally, Praxis received a Breakthrough Therapy De...
08-06 12:00
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted 7,318 restricted stock units to 29 new non-executive employees under its 2024 Inducement Plan. The awards vest annually over four years and are intended to incentivize employment. The company focuses on CNS disorders using genetic insights and proprietary platforms.
08-04 20:01
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target
BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $810 price target.
07-29 18:31
